DK3342879T3 - Fremgangsmåder til forudsigelse af lægemiddelmodtagelighed hos cancerpatienter - Google Patents
Fremgangsmåder til forudsigelse af lægemiddelmodtagelighed hos cancerpatienter Download PDFInfo
- Publication number
- DK3342879T3 DK3342879T3 DK17211034.8T DK17211034T DK3342879T3 DK 3342879 T3 DK3342879 T3 DK 3342879T3 DK 17211034 T DK17211034 T DK 17211034T DK 3342879 T3 DK3342879 T3 DK 3342879T3
- Authority
- DK
- Denmark
- Prior art keywords
- sensitivity
- procedures
- cancer patients
- preventing pharmaceutical
- pharmaceutical
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440883P | 2016-12-30 | 2016-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3342879T3 true DK3342879T3 (da) | 2019-09-23 |
Family
ID=60856935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17211034.8T DK3342879T3 (da) | 2016-12-30 | 2017-12-29 | Fremgangsmåder til forudsigelse af lægemiddelmodtagelighed hos cancerpatienter |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10907214B2 (da) |
| EP (1) | EP3342879B1 (da) |
| CN (1) | CN108265106B (da) |
| AU (1) | AU2017258901A1 (da) |
| CA (1) | CA2990273A1 (da) |
| DK (1) | DK3342879T3 (da) |
| HK (1) | HK1255416B (da) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| DK3198035T3 (da) | 2014-09-26 | 2023-01-30 | Allarity Therapeutics Europe ApS | Fremgangsmåder til forudsigelse af medicinrespons |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2018202878A1 (en) | 2017-05-16 | 2018-12-06 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| WO2019173456A1 (en) * | 2018-03-06 | 2019-09-12 | Board Of Regents, The University Of Texas System | Replication stress response biomarkers for immunotherapy response |
| CN108913773A (zh) * | 2018-07-12 | 2018-11-30 | 温州医科大学 | 一种临床评价卵巢癌铂类药物化疗敏感性的多分子标志物及其装置与评价方法 |
| EP3888021B1 (en) * | 2018-11-30 | 2024-02-21 | Caris MPI, Inc. | Next-generation molecular profiling |
| WO2020146678A2 (en) * | 2019-01-10 | 2020-07-16 | Research Institute At Nationwide Children's Hospital | Methods to identify and treat cisplatin-resistant ovarian cancer |
| CN111424083A (zh) * | 2019-01-10 | 2020-07-17 | 北京医院 | 一种白血病标志物及其在白血病预后评估中的用途 |
| CA3148611A1 (en) | 2019-08-12 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| CN110714078B (zh) * | 2019-09-29 | 2021-11-30 | 浙江大学 | 一种用于ii期结直肠癌复发预测的标记基因及应用 |
| CA3163319A1 (en) * | 2019-12-02 | 2021-06-10 | Caris Mpi, Inc. | Pan-cancer platinum response predictor |
| KR102263983B1 (ko) * | 2020-02-12 | 2021-06-11 | 씨비에스바이오사이언스 주식회사 | 간세포 종양에 있어서 소라페닙 치료의 감수성을 증가시키기 위한 분석방법 |
| KR102222520B1 (ko) * | 2020-09-04 | 2021-03-05 | 연세대학교 산학협력단 | 약물 반응성 예측용 조성물 및 이의 용도 |
| CN113025713B (zh) * | 2021-02-23 | 2022-11-22 | 浙江东睿生物科技有限公司 | 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用 |
| CN113667752A (zh) * | 2021-09-09 | 2021-11-19 | 菲思特(上海)生物科技有限公司 | 一种用于柔红霉素代谢标志物的检测试剂盒及其检测方法和应用 |
| CN114768091A (zh) * | 2022-03-28 | 2022-07-22 | 湖南安泰康成生物科技有限公司 | 结肠癌治疗系统以及结肠癌治疗的交变电场发生装置 |
| CN114948973A (zh) * | 2022-04-12 | 2022-08-30 | 哈尔滨医科大学 | 硼替佐米与索拉非尼联合在制备治疗肾透明细胞癌药物中的用途 |
| AU2024267174A1 (en) | 2023-05-08 | 2025-11-13 | Chosa Oncology Ab | Liposome compositions and medical uses thereof |
| CN116726008B (zh) * | 2023-05-11 | 2025-05-16 | 中国人民解放军总医院第二医学中心 | 阿那曲唑在制备治疗淋巴瘤的药物中的用途 |
| DE102023114015B3 (de) | 2023-05-26 | 2024-09-12 | Precision For Medicine Gmbh | ITGA4 als epigenetischer Marker für die Identifizierung von Immunzellen |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US4963362A (en) | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
| US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US6027726A (en) | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US20040072722A1 (en) | 2002-10-10 | 2004-04-15 | Kornblith Paul L. | Methods for assessing efficacy of chemotherapeutic agents |
| AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
| US20020006613A1 (en) | 1998-01-20 | 2002-01-17 | Shyjan Andrew W. | Methods and compositions for the identification and assessment of cancer therapies |
| AU1814800A (en) | 1998-11-05 | 2000-05-22 | Parker Hughes Institute | (Ikaros) isoforms and mutants |
| JP2000224989A (ja) * | 1998-11-20 | 2000-08-15 | Asahi Breweries Ltd | 制癌剤感受性試験方法 |
| DE69941488D1 (de) | 1998-11-25 | 2009-11-12 | British Telecomm | Nachrichtensystem |
| EP1137945A1 (en) | 1998-12-08 | 2001-10-04 | Board of Regents, The University of Texas System | Methods for detection of antiestrogen-resistant breast cancer |
| EP1140137A2 (en) | 1998-12-18 | 2001-10-10 | Scios Inc. | Method for detection and use of differentially expressed genes in disease states |
| US7324926B2 (en) | 1999-04-09 | 2008-01-29 | Whitehead Institute For Biomedical Research | Methods for predicting chemosensitivity or chemoresistance |
| US6647341B1 (en) | 1999-04-09 | 2003-11-11 | Whitehead Institute For Biomedical Research | Methods for classifying samples and ascertaining previously unknown classes |
| US6911306B1 (en) | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
| AU2001245295A1 (en) | 2000-02-17 | 2001-08-27 | Millennum Pharmaceuticals, Inc. | Methods and compositions for the identification, assessment, prevention and therapy of human cancers |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| ES2387886T3 (es) | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| JP2006506945A (ja) | 2002-03-28 | 2006-03-02 | メディカル・カレッジ・オブ・オハイオ | 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物 |
| JP2004043446A (ja) | 2002-05-15 | 2004-02-12 | Schering Ag | ヒストンデアセチラーゼ抑制剤及びその使用 |
| CA2752124A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer |
| US7273620B1 (en) | 2002-05-20 | 2007-09-25 | University Of British Columbia | Triggered release of liposomal drugs following mixing of cationic and anionic liposomes |
| US20040018525A1 (en) | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| DE60335469D1 (de) | 2002-07-02 | 2011-02-03 | Univ Texas | Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren |
| EP1643971A2 (en) | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005014856A1 (en) | 2003-08-08 | 2005-02-17 | Canbas Co., Ltd. | Sensitivity test to predict efficacy of anti-cancer therapies |
| WO2005032347A2 (en) | 2003-10-01 | 2005-04-14 | The Ohio State University Research Foundation | Determining the chemosensitivity of cells to cytotoxic agents |
| US20080113344A1 (en) | 2003-10-28 | 2008-05-15 | Ralph Wirtz | Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment |
| US7879545B2 (en) | 2003-11-05 | 2011-02-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier |
| US20050147978A1 (en) | 2003-12-30 | 2005-07-07 | Jose Remacle | Method for quantitative determination of multi-drug resistance in tumors |
| CN102989009B (zh) | 2003-12-31 | 2015-06-03 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| US20050227266A1 (en) | 2004-02-06 | 2005-10-13 | Ross Douglas T | Biomarker:compound correlations in cancer diagnosis and therapy |
| CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| JP2007528730A (ja) | 2004-03-12 | 2007-10-18 | ザ クイーンズ ユニヴァーシティ オブ ベルファスト | 治療および測定法 |
| CA2561835A1 (en) | 2004-03-30 | 2005-10-13 | Den Kgl. Veterinaer-Og Landbohojskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors |
| ES2636470T3 (es) | 2004-04-09 | 2017-10-05 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| JP5697297B2 (ja) | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| WO2006025411A1 (ja) | 2004-08-31 | 2006-03-09 | Astellas Pharm. Inc. | 細胞内薬物送達改善リポソーム |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| CA2624086A1 (en) | 2005-09-28 | 2007-04-05 | H. Lee Moffitt Cancer Center | Individualized cancer treatments |
| EP1951239A2 (en) | 2005-10-25 | 2008-08-06 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EP1969147B1 (en) | 2006-01-05 | 2014-07-30 | The Ohio State University Research Foundation | microRNA-based methods for the diagnosis of stomach cancer |
| US20090221435A1 (en) | 2006-02-08 | 2009-09-03 | Dharmacon, Inc. | Microarray for detecting and quantifying microrna |
| WO2008006517A2 (en) | 2006-07-13 | 2008-01-17 | Siemens Healthcare Diagnostics Gmbh | Prediction of breast cancer response to taxane-based chemotherapy |
| EP2046288B1 (en) | 2006-07-14 | 2013-07-03 | FMC Biopolymer AS | Hydrogels containing low molecular weight alginates and biostructures made therefrom |
| US20080076134A1 (en) | 2006-09-21 | 2008-03-27 | Nuclea Biomarkers, Llc | Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan |
| WO2008073629A2 (en) | 2006-11-03 | 2008-06-19 | Board Of Regents, The University Of Texas System | Bifunctional predictors of cancer treatment sensitivity and resistance |
| EP2136911A2 (en) | 2007-01-19 | 2009-12-30 | Biodot, Inc. | Systems and methods for high speed array printing and hybridization |
| WO2008112283A2 (en) | 2007-03-12 | 2008-09-18 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment |
| WO2008138578A2 (en) | 2007-05-11 | 2008-11-20 | Medical Prognosis Institute | Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2009036332A1 (en) | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009038779A2 (en) | 2007-09-19 | 2009-03-26 | University Of Tennessee Research Foundation | Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents |
| US20100240043A1 (en) | 2007-10-19 | 2010-09-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| CN102002490A (zh) | 2009-08-31 | 2011-04-06 | 上海市肿瘤研究所 | 9个用于预测原发性肝癌是否复发的microRNA标志物 |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| DK177529B1 (en) | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
| MX337650B (es) | 2009-11-23 | 2016-03-14 | Genomic Health Inc | Metodos para predecir el desenlace clinico del cancer. |
| US20120302626A1 (en) | 2009-12-04 | 2012-11-29 | Sandeep Dave | Microrna and use thereof in identification of b cell malignancies |
| EP2516681B1 (en) | 2010-02-11 | 2017-10-18 | Nanostring Technologies, Inc | Compositions and methods for the detection of preferably small rnas by bridge hybridisation and ligation |
| WO2011098578A2 (en) * | 2010-02-12 | 2011-08-18 | Bioneer A/S | Liposome system for ocular administration |
| US20130059015A1 (en) | 2010-03-11 | 2013-03-07 | H. Lee Moffitt Cancer Center & Research Institute | Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response |
| US20110229888A1 (en) | 2010-03-16 | 2011-09-22 | Hengen Paul N | Compositions and Methods for the Detection of Genomic Features |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| CA2808417A1 (en) | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| US20120046186A1 (en) | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| WO2012109233A2 (en) | 2011-02-07 | 2012-08-16 | Board Of Regents, The University Of Texas System | Methods for predicting recurrence risk in breast cancer patients |
| AU2012265177B2 (en) | 2011-06-01 | 2017-03-02 | Medical Prognosis Institute A/S | Methods and devices for prognosis of cancer relapse |
| CA2839705A1 (en) | 2011-06-24 | 2012-12-27 | Nanostring Technologies, Inc. | Multivariate diagnostic assays and methods for using same |
| WO2013040393A2 (en) | 2011-09-14 | 2013-03-21 | Georgetown University | Genes contributing to survival of cancer cells |
| WO2013130465A2 (en) | 2012-02-27 | 2013-09-06 | Genomic Health, Inc. | Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs |
| EP2641916A1 (en) * | 2012-03-23 | 2013-09-25 | Centre National de la Recherche Scientifique (C.N.R.S) | Novel antibodies anti-sPLA2-IIA and uses thereof |
| EP2968551B1 (en) * | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| US9606123B2 (en) * | 2013-03-29 | 2017-03-28 | University Of Virginia Patent Foundation | Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment |
| RU2528247C2 (ru) | 2013-05-07 | 2014-09-10 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов и набор для его осуществления |
| US10392667B2 (en) | 2013-06-07 | 2019-08-27 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2015051466A1 (en) * | 2013-10-11 | 2015-04-16 | UNIVERSITé LAVAL | Extracellular mitochondrial components for detecting inflammatory reactions and conditions |
| DK3198035T3 (da) | 2014-09-26 | 2023-01-30 | Allarity Therapeutics Europe ApS | Fremgangsmåder til forudsigelse af medicinrespons |
| WO2016077579A1 (en) * | 2014-11-14 | 2016-05-19 | The Regents Of The University Of California | Suppression of spla2-integrin binding for treating an inflammatory condition or suppressing cell proliferation |
| US20160199399A1 (en) | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
| US20180087113A1 (en) | 2016-09-27 | 2018-03-29 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
-
2017
- 2017-11-09 AU AU2017258901A patent/AU2017258901A1/en not_active Abandoned
- 2017-12-27 CA CA2990273A patent/CA2990273A1/en active Pending
- 2017-12-29 CN CN201711498528.6A patent/CN108265106B/zh active Active
- 2017-12-29 US US15/858,703 patent/US10907214B2/en active Active
- 2017-12-29 DK DK17211034.8T patent/DK3342879T3/da active
- 2017-12-29 EP EP17211034.8A patent/EP3342879B1/en active Active
-
2018
- 2018-11-15 HK HK18114579.0A patent/HK1255416B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2990273A1 (en) | 2018-06-30 |
| HK1257884A1 (zh) | 2019-11-01 |
| CN108265106B (zh) | 2022-11-29 |
| US10907214B2 (en) | 2021-02-02 |
| HK1255416B (en) | 2020-04-29 |
| US20180202004A1 (en) | 2018-07-19 |
| AU2017258901A1 (en) | 2018-07-19 |
| EP3342879A1 (en) | 2018-07-04 |
| CN108265106A (zh) | 2018-07-10 |
| EP3342879B1 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3342879T3 (da) | Fremgangsmåder til forudsigelse af lægemiddelmodtagelighed hos cancerpatienter | |
| IL282304A (en) | Topical pharmaceutical compositions | |
| IL290823A (en) | Pharmaceutical compositions for combination therapy | |
| DK3554681T3 (da) | Fremgangsmåde til proteincorona-sensorarray til tidlig detektering af sygdomme | |
| UA37801S (uk) | Пристрій для інтраназального введення ліків | |
| DK3616720T3 (da) | Farmaceutisk sammensætning til cancerbehandling | |
| EP3463228A4 (en) | INTRAOCULAR DELIVERY | |
| DK3797742T3 (da) | Indretning til suprakoroidal indgivelse af terapeutisk middel | |
| DK3139986T3 (da) | System til administration af terapeutisk gas | |
| DK3378482T3 (da) | Formulering til administration af antitumorlægemiddel | |
| SI3529248T1 (sl) | Farmacevtske spojine | |
| DK3302638T3 (da) | Anordning til indgivelse af lægemidler | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3356313T3 (da) | 2-perfluorhexyloktan til oftalmisk indgivelse | |
| BR112017018931A2 (pt) | formulações farmacêuticas de um inibidor de tirosina quinase de bruton | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3357491T3 (da) | Farmaceutisk sammensætning til afgivelse af et anionisk medikament | |
| DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
| DK3325080T3 (da) | Fremgangsmåder til bedre indgivelse af aktive midler til tumorer | |
| HUE055209T2 (hu) | Terápiásan aktív vegyületek gyógyszerészeti készítményei | |
| DK3237045T3 (da) | Indretning til indgivelse af lægemidler | |
| HUE052107T2 (hu) | Gyógyszerészeti vegyületek | |
| DK3681483T3 (da) | Fremgangsmåde til lyofiliseret farmaceutisk formulering af et terapeutisk protein | |
| IL257902A (en) | Medicament vial assembly |